Research and Markets has announced the addition of the "Multiple Myeloma Pipeline Highlights - 2017" drug pipelines to their offering.

Multiple Myeloma Pipeline Highlights - 2017, provides most up-to-date information on key pipeline products in the global Multiple Myeloma market. It covers emerging therapies for Multiple Myeloma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Multiple Myeloma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Multiple Myeloma pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Multiple Myeloma pipeline products by the company.

Short-term Launch Highlights:

Find out which Multiple Myeloma pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Multiple Myeloma Pipeline by Stages

2. Multiple Myeloma Pipeline by Drug Class

3. Multiple Myeloma Pipeline by Company

4. Multiple Myeloma Phase 3 Clinical Trial Insights

5. Multiple Myeloma Phase 2 Clinical Trial Insights

6. Multiple Myeloma Phase 1 Clinical Trial Insights

7. Multiple Myeloma Preclinical Research Insights

8. Multiple Myeloma Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/wk299b/multiple_myeloma